Portal de Periódicos da CAPES

Pressor Response to Intravenous Tyramine in Healthy Subjects After Safinamide, a Novel Neuroprotectant With Selective, Reversible Monoamine Oxidase B Inhibition

2003; Lippincott Williams & Wilkins; Volume: 26; Issue: 4 Linguagem: Inglês

10.1097/00002826-200307000-00012

1537-162X

C. Cattaneo, Carla Caccia, A Marzo, Roberto Maj, Ruggero G. Fariello,

Neurotransmitter Receptor Influence on Behavior

Safinamide is a novel neuroprotectant combining sodium and calcium channel blocking properties with selective, reversible monoamine oxidase type B (MAO B) inhibition. Phase 1 studies have demonstrated that in healthy volunteers, the ED50 (a dose that inhibits enzyme activity by 50% in 50% of treated subjects) for MAO B inhibition is 87.5 μg/kg/day orally, and that no MAO A inhibition occurs after 10-mg/kg oral dosing. To assess the risk of inducing the "cheese effect," the effect of safinamide and placebo on the pressor response to tyramine was investigated in a group of healthy male volunteers. The study was an open, single-dose placebo-controlled trial with the 2 treatments in sequence. An increase of 30 mm Hg systolic blood pressure was obtained by intravenous tyramine administered by 0.5-mg incremental boluses injected at 15-minute intervals. The amount of tyramine necessary to achieve such a blood pressure increase was the same after the safinamide 2-mg/kg oral load compared with placebo. These results suggest that dietary restrictions for food with high tyramine content should not be required under safinamide treatment.